Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.

Nicholas James, MR Sydes, MD Mason, NW Clarke, DP Dearnaley, J Dwyer, G Jovic, AW Ritchie, JM Russell, K Sanders, GN Thalmann, G Bertelli, AJ Birtle, JM O'Sullivan, A Protheroe, D Sheehan, N Srihari, MK Parmar

Research output: Contribution to journal › Article

86 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.'. Together they form a unique fingerprint.

Medicine & Life Sciences